267 related articles for article (PubMed ID: 37287049)
1. Review immune response of targeting CD39 in cancer.
Liu Y; Li Z; Zhao X; Xiao J; Bi J; Li XY; Chen G; Lu L
Biomark Res; 2023 Jun; 11(1):63. PubMed ID: 37287049
[TBL] [Abstract][Full Text] [Related]
2. CD39/CD73/A2AR pathway and cancer immunotherapy.
Xia C; Yin S; To KKW; Fu L
Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386
[TBL] [Abstract][Full Text] [Related]
3. CD39 - A bright target for cancer immunotherapy.
Guo S; Han F; Zhu W
Biomed Pharmacother; 2022 Jul; 151():113066. PubMed ID: 35550530
[TBL] [Abstract][Full Text] [Related]
4. Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism.
Spatola BN; Lerner AG; Wong C; Dela Cruz T; Welch M; Fung W; Kovalenko M; Losenkova K; Yegutkin GG; Beers C; Corbin J; Soros VB
MAbs; 2020; 12(1):1838036. PubMed ID: 33146056
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.
Kurago Z; Guo G; Shi H; Bollag RJ; Groves MW; Byrd JK; Cui Y
Front Immunol; 2023; 14():1212209. PubMed ID: 37435071
[TBL] [Abstract][Full Text] [Related]
6. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
[TBL] [Abstract][Full Text] [Related]
7. Adenosine Generated by Regulatory T Cells Induces CD8
Shi L; Feng M; Du S; Wei X; Song H; Yixin X; Song J; Wenxian G
Biomed Res Int; 2019; 2019():4093214. PubMed ID: 31930120
[TBL] [Abstract][Full Text] [Related]
8. The abnormal function of CD39
Lu Y; Cheng L; Li F; Ji L; Shao X; Wu B; Zhan Y; Liu C; Min Z; Ke Y; Sun L; Chen H; Cheng Y
Ann Hematol; 2019 Aug; 98(8):1845-1854. PubMed ID: 31154474
[TBL] [Abstract][Full Text] [Related]
9. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy.
Augustin RC; Leone RD; Naing A; Fong L; Bao R; Luke JJ
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135866
[TBL] [Abstract][Full Text] [Related]
10. On the mechanism of anti-CD39 immune checkpoint therapy.
Allard D; Allard B; Stagg J
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098829
[TBL] [Abstract][Full Text] [Related]
11. Regulatory role of CD39 and CD73 in tumor immunity.
Kaplinsky N; Williams K; Watkins D; Adams M; Stanbery L; Nemunaitis J
Future Oncol; 2024 Apr; ():1-14. PubMed ID: 38652041
[TBL] [Abstract][Full Text] [Related]
12. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
14. Adenosine metabolized from extracellular ATP ameliorates organ injury by triggering A
Kelestemur T; Németh ZH; Pacher P; Beesley J; Robson SC; Eltzschig HK; Haskó G
Respir Res; 2023 Jul; 24(1):186. PubMed ID: 37438813
[TBL] [Abstract][Full Text] [Related]
15. Preventing ATP Degradation by ASO-Mediated Knockdown of CD39 and CD73 Results in A2aR-Independent Rescue of T Cell Proliferation.
Festag J; Thelemann T; Schell M; Raith S; Michel S; Jaschinski F; Klar R
Mol Ther Nucleic Acids; 2020 Sep; 21():656-669. PubMed ID: 32739778
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD39 in cancer.
Moesta AK; Li XY; Smyth MJ
Nat Rev Immunol; 2020 Dec; 20(12):739-755. PubMed ID: 32728220
[TBL] [Abstract][Full Text] [Related]
17. The expression of the adenosine pathway markers CD39 and CD73 in salivary gland carcinomas harbors the potential for novel immune checkpoint inhibition.
Bauer A; Gebauer N; Knief J; Tharun L; Arnold N; Riecke A; Steinestel K; Witte HM
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3193-3208. PubMed ID: 35902382
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.
Schäkel L; Mirza S; Winzer R; Lopez V; Idris R; Al-Hroub H; Pelletier J; Sévigny J; Tolosa E; Müller CE
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981785
[TBL] [Abstract][Full Text] [Related]
19. Adenosine in cancer immunotherapy: Taking off on a new plane.
Zhang C; Wang K; Wang H
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189005. PubMed ID: 37913941
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.
Häusler SF; Del Barrio IM; Diessner J; Stein RG; Strohschein J; Hönig A; Dietl J; Wischhusen J
Am J Transl Res; 2014; 6(2):129-39. PubMed ID: 24489992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
